Physician profile
Reed Larson
NPI 1245732619
$2,567.35
in general payments reported to CMS, 2019-2025
21 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $252 · 2022: $136 · 2023: $308 · 2024: $859 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,179.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $918.29 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $260.82 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $252.16 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $251.00 | 2024-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $219.57 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Abbott Laboratories | $96.26 | 2024-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $96.01 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $85.76 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $73.23 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Abbvie INC. | $41.32 | 2023 | |
| Dynavax Technologies Corporation | $34.76 | 2023-2024 | Heplisav-B |
| Inspire Medical Systems, INC. | $29.26 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $29.14 | 2024 | |
| Medtronic, INC. | $28.25 | 2025 | Minimed 780g |
| Zimmer Biomet Holdings, INC. | $25.60 | 2025 | Mymobility Platform |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $24.23 | 2024 | Hillrom - Monarch Airway Clearance System |
| Amgen INC. | $23.43 | 2025 | Krystexxa |
| Gilead Sciences, INC. | $22.80 | 2023 | |
| Astellas Pharma US INC | $22.25 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $17.68 | 2023 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $15.53 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reed Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.